Trial Profile
An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ACT-SURE-LTE
- Sponsors Roche
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 05 Jul 2017 New trial record